The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
NLRP3 inflammasome activation is required for fibrosis development in NAFLD
Open accessAbstract
NLR inflammasomes, caspase 1 activation platforms critical for processing key pro-inflammatory cytokines, have been implicated in the development of nonalcoholic fatty liver disease (NAFLD). As the direct role of the NLRP3 inflammasome remains unclear, we tested effects of persistent NLRP3 activation as a contributor to NAFLD development and, in particular, as a modulator of progression from benign hepatic steatosis to steatohepatitis during diet-induced NAFLD. Gain of function tamoxifen-inducible Nlrp3 knock-in mice allowing for in vivo temporal control of NLRP3 activation and loss of function Nlrp3 knockout mice were placed on short-term choline-deficient amino acid-defined (CDAA) diet, to induce isolated hepatic steatosis or long-term CDAA exposure, to induce severe steatohepatitis and fibrosis, respectively. Expression of NLRP3 associated proteins was assessed in liver biopsies of a well-characterized group of patients with the full spectrum of NAFLD. Nlrp3(-/-) mice were protected from long-term feeding CDAA-induced hepatomegaly, liver injury, and infiltration of activated macrophages. More importantly, Nlrp3(-/-) mice showed marked protection from CDAA-induced liver fibrosis. After 4 weeks on CDAA diet, wild-type (WT) animals showed isolated hepatic steatosis while Nlrp3 knock-in mice showed severe liver inflammation, with increased infiltration of activated macrophages and early signs of liver fibrosis. In the liver samples of patients with NAFLD, inflammasome components were significantly increased in those patients with nonalcoholic steatohepatitis (NASH) when compared to those with non-NASH NAFLD with mRNA levels of pro-IL1 beta correlated to levels of COL1A1. Our study uncovers a crucial role for the NLRP3 inflammasome in the development of NAFLD. These findings may lead to novel therapeutic strategies aimed at halting the progression of hepatic steatosis to the more severe forms of this disease. Key message: Mice with NLRP3 inflammasome loss of function are protected from diet-induced steatohepatitis. NLRP3 inflammasome gain of function leads to early and severe onset of diet-induced steatohepatitis in mice. Patients with severe NAFLD exhibit increased levels of NLRP3 inflammasome components and levels of pro-IL1β mRNA correlate with the expression of COL1A1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sen cells showed altered lipid-transport and lipoprotein-remodelling traits (Fig. 3a), consistent with the ability of oxidative stress to generate lipotoxicity that triggers inflammation and fibrosis30.”
From Senescence atlas reveals an aged-like inflamed niche that blunts muscle regeneration (2023) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [289]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Self-citationThe NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Self-citationFatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T.-H., Brickey, W. J., & Ting, J. P.-Y. (2011) · Nature Immunology · doi:10.1038/ni.2022 · Cited by 1,698
Cited by
Sorted by citations
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Dietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110
Self-citationThe role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Self-citationThe role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Inflammasome activation and function in liver disease
Szabó, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 600
Gaul, S., Leszczynska, A., Alegre, F., Kaufmann, B. K., Johnson, C. D., Adams, L. A., Wree, A., Damm, G., Seehofer, D., Calvente, C. J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.041 · Cited by 559
Self-citationInnate Immunity and Inflammation in NAFLD/NASH
Arrese, M. A., Cabrera, D., Kalergis, A. M., & Feldstein, A. E. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4049-x · Cited by 507
Self-citationPierantonelli, I., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 473
Senescence atlas reveals an aged-like inflamed niche that blunts muscle regeneration
Moiseeva, V., Cisneros, A., Sica, V., Deryagin, O., Lai, Y., Jung, S., Andrés, E., An, J., Segalés, J., Ortet, L., et al. (2023) · Nature · doi:10.1038/s41586-022-05535-x · Cited by 423
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
Parthasarathy, G., Revelo, X. S., & Malhi, H. (2020) · Hepatology Communications · doi:10.1002/hep4.1479 · Cited by 430
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 424
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Walle, L. V., & Lamkanfi, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00822-2 · Cited by 397
Wan, X., Xu, C., Lin, Y., Lü, C., Li, D., Sang, J., He, H., Liu, X., Li, Y., & Yu, C. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.022 · Cited by 371
Role of inflammatory response in liver diseases: Therapeutic strategies
Campo, J. A. D., Gallego, P., & Grande, L. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i1.1 · Cited by 348
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
Tilg, H., Moschen, A. R., & Szabó, G. (2016) · Hepatology · doi:10.1002/hep.28456 · Cited by 319
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Argüello, G., Balboa, E., Arrese, M. A., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 320
Pathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 291
Role of the Inflammasome in Liver Disease
Ribeiro, M. D. C., & Szabó, G. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032521-102529 · Cited by 286
NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice
Wree, A., McGeough, M. D., Inzaugarat, M. E., Eguchi, A., Schuster, S., Johnson, C. D., Peña, C. A., Geisler, L. J., Papouchado, B. G., Hoffman, H. M., et al. (2018) · Hepatology · doi:10.1002/hep.29523 · Cited by 266
Self-citationWang, X., He, Q., Zhou, C., Xu, Y., Liu, D., Fujiwara, N., Kubota, N., Click, A., Henderson, P., Vancil, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.11.013 · Cited by 262
Sun, L., Ma, L., Ma, Y., Zhang, F., Zhao, C., & Nie, Y. (2018) · Protein & Cell · doi:10.1007/s13238-018-0546-3 · Cited by 263
Athyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S., Goudevenos, J., Elisaf, M. S., Germanidis, G., Giouleme, O., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.014 · Cited by 219
Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
Svegliati‐Baroni, G., Pierantonelli, I., Torquato, P., Marinelli, R., Ferreri, C., Chatgilialoglu, C., Bartolini, D., & Galli, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.029 · Cited by 255
Ma, Q. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000629 · Cited by 260
Tanwar, S., Rhodes, F., Srivastava, A., Trembling, P. M., & Rosenberg, W. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i2.109 · Cited by 261
Inflammasome Priming in Sterile Inflammatory Disease
Patel, M. N., Carroll, R. G., Galván-Peña, S., Mills, E. L., Olden, R., Triantafilou, M., Wolf, A. I., Bryant, C. E., Triantafilou, K., & Masters, S. L. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.007 · Cited by 241
Molecular mechanisms of subretinal fibrosis in age-related macular degeneration
Ishikawa, K., Kannan, R., & Hinton, D. R. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.03.009 · Cited by 238
Melatonin as an anti-inflammatory agent modulating inflammasome activation
Favero, G., Franceschetti, L., Bonomini, F., Rodella, L. F., & Rezzani, R. (2017) · International Journal of Endocrinology · doi:10.1155/2017/1835195 · Cited by 233
Mihm, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103104 · Cited by 232
Wang, D., Weng, Y., Zhang, Y., Wang, R., Wang, T., Zhou, J., Shen, S., Wang, H., & Wang, Y. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.141049 · Cited by 233
Microbiota and Fatty Liver Disease—the Known, the Unknown, and the Future
Lang, S., & Schnabl, B. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.007 · Cited by 244
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Fatty Acids and NLRP3 Inflammasome–Mediated Inflammation in Metabolic Tissues
Ralston, J. C., Lyons, C. L., Kennedy, E. B., Kirwan, A. M., & Roche, H. M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064836 · Cited by 231
Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
Yan, T., Yan, N., Wang, P., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.017 · Cited by 226
Kim, S. H., Kim, G., Han, D. H., Lee, M., Kim, I. K., Kim, B., Kim, K. H., Song, Y.-M., Yoo, J. E., Wang, H. J., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1356977 · Cited by 225
Immunological mechanisms and therapeutic targets of fatty liver diseases
Wang, H., Mehal, W. Z., Nagy, L. E., & Rotman, Y. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00579-3 · Cited by 234
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 239
Therapeutic modulation of inflammasome pathways
Chauhan, D., Walle, L. V., & Lamkanfi, M. (2020) · Immunological Reviews · doi:10.1111/imr.12908 · Cited by 219
Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame
Ibrahim, S. H., Hirsova, P., Malhi, H., & Gores, G. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3977-1 · Cited by 218
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 214
Molecular Pathogenesis of NASH
Caligiuri, A., Gentilini, A., & Marra, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091575 · Cited by 219
Hepatic NAD+ deficiency as a therapeutic target for non‐alcoholic fatty liver disease in ageing
Zhou, C., Yang, X., Hua, X., Liu, J., Fan, M.-B., Li, G., Song, J., Xu, T., Li, Z., Guan, Y., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13513 · Cited by 202
The role of the gut microbiota in metabolic health
Janssen, A. W. F., & Kersten, S. (2015) · The FASEB Journal · doi:10.1096/fj.14-269514 · Cited by 209
Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis
Hirsova, P., & Gores, G. J. (2014) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2014.11.005 · Cited by 201
Arias, N., Arboleya, S., Allison, J., Kaliszewska, A., Higarza, S. G., Gueimonde, M., & Arias, J. L. (2020) · Nutrients · doi:10.3390/nu12082340 · Cited by 210
Robert, S., Gicquel, T., Victoni, T., Valença, S., Barreto, E., Bailly-Maître, B., Boichot, E., & Lagente, V. (2016) · Bioscience Reports · doi:10.1042/bsr20160107 · Cited by 190
Sözen, E., & Özer, N. K. (2017) · Redox Biology · doi:10.1016/j.redox.2017.02.025 · Cited by 188
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1109938 · Cited by 203
Inflammasomes in liver fibrosis
Alegre, F., Pelegrin, P., & Feldstein, A. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1601350 · Cited by 176
Self-citationPathophysiological mechanisms underlying MAFLD
Kuchay, M. S., Choudhary, N. S., & Mishra, S. K. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.026 · Cited by 188
Corcoran, S. E., Halai, R., & Cooper, M. A. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000171 · Cited by 180
Kushiyama, A., Nakatsu, Y., Matsunaga, Y., Yamamotoya, T., Mori, K., Ueda, K., Inoue, Y., Sakoda, H., Fujishiro, M., Ono, H., et al. (2016) · Mediators of Inflammation · doi:10.1155/2016/8603164 · Cited by 188
Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
Wan, X., Xu, C., Yu, C., & Li, Y. (2016) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2016/6489012 · Cited by 176
Qiu, T., Pei, P., Yao, X., Jiang, L., Wei, S., Wang, Z., Bai, J., Yang, G., Gao, N., Yang, L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1004-0 · Cited by 171
Gan, L., Feng, Y., Du, B., Fu, H., Tian, Z., Xue, G., Yan, C., Cui, X., Zhang, R., Cui, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39028-w · Cited by 162
Pyroptosis in Liver Disease: New Insights into Disease Mechanisms
Wu, J., Lin, S., Wan, B., Velani, B., & Zhu, Y. (2019) · Aging and Disease · doi:10.14336/ad.2019.0116 · Cited by 157
Inzaugarat, M. E., Johnson, C. D., Holtmann, T. M., McGeough, M. D., Trautwein, C., Papouchado, B. G., Schwabe, R., Hoffman, H. M., Wree, A., & Feldstein, A. E. (2019) · Hepatology · doi:10.1002/hep.30252 · Cited by 148
Self-citationWei, Q., Guo, P., Mu, K., Zhang, Y., Zhao, W., Huai, W., Qiu, Y., Li, T., Ma, X., Liu, Y., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.63 · Cited by 146
IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies
Mirea, A.-M., Tack, C. J., Chavakis, T., Joosten, L. A. B., & Toonen, E. J. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.005 · Cited by 151
Wettstein, G., Luccarini, J., Poekes, L., Faye, P., Kupkowski, F., Adarbes, V., Defrêne, E., Estivalet, C., Gawronski, X., Jantzen, I., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1057 · Cited by 137
Mai, W., Xu, Y., Xu, J., Zhao, D., Ye, L., Yu, G., Wang, Z., Lu, Q., Lin, J., Yang, T., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00185 · Cited by 129
Wang, Y., Chen, C., Chen, J., Sang, T., Peng, H., Lin, X., Zhao, Q., Chen, S., Eling, T. E., & Wang, X. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102322 · Cited by 130
Relevance of the NLRP3 Inflammasome in the Pathogenesis of Chronic Liver Disease
Wu, X., Dong, L., Lin, X., & Li, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01728 · Cited by 122
Yu, L., Hong, W., Lu, S., Li, Y., Guan, Y., Weng, X., & Feng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.780496 · Cited by 126
Depression and chronic liver diseases: are there shared underlying mechanisms?
Huang, X., Liu, X., & Yu, Y. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00134 · Cited by 121
Rovira‐Llopis, S., Apostolova, N., Bañuls, C., Muntané, J., Rocha, M., & Víctor, V. M. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7313 · Cited by 125
Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases
Seok, J. K., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01307-9 · Cited by 122
Schneider, K. M., Bieghs, V., Heymann, F., Hu, W., Yildiz, D., Liao, L., Frissen, M., Ludwig, A., Gaßler, N., Pabst, O., et al. (2015) · Hepatology · doi:10.1002/hep.27982 · Cited by 112
Zhang, B., Xu, D., She, L., Wang, Z., Yang, N., Sun, R., Zhang, Y., Yan, C., Wei, Q., Aa, J., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700602r · Cited by 112
Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways
Lv, Y., Gao, X., Luo, Y., Fan, W., Shen, T., Ding, C., Yao, M., Song, S., & Yan, L. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.05.015 · Cited by 108
Li, Y., Wang, P., Yang, X., Wang, W., Zhang, J., He, Y., Zhang, W. K., Jing, T., Wang, B., & Lin, R. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.07.018 · Cited by 107
Magee, N. S., Zou, A., & Zhang, Y. (2016) · BioMed Research International · doi:10.1155/2016/5170402 · Cited by 114
The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms
Jasirwan, C. O. M., Lesmana, C. R. A., Hasan, I., Sulaiman, A. S., & Gani, R. A. (2019) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.18-032 · Cited by 114
Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation
Yan, T., Wang, H., Cao, L.-J., Wang, Q., Takahashi, S., Yagai, T., Li, G.-L., Krausz, K., Wang, G.-J., Gonzalez, F., et al. (2018) · Drug Metabolism And Disposition · doi:10.1124/dmd.118.082008 · Cited by 98
Regulating metabolic inflammation by nutritional modulation
Charles‐Messance, H., Mitchelson, K. A. J., Castro, E. D. M., Sheedy, F. J., & Roche, H. M. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.08.013 · Cited by 121
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Arrese, M. A., Arab, J. P., Francisco Barrera, M., Kaufmann, B. K., Valenti, L. V. C., & Feldstein, A. E. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730927 · Cited by 109
Self-citationRahim, I., Djerdjouri, B., Sayed, R. K. A., Fernández‐Ortiz, M., Fernández-Gil, B. I., Hidalgo‐Gutiérrez, A., López, L. C., Escames, G., Reiter, R. J., & Acuña-Castroviejo, D. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12410 · Cited by 103
Hou, L., Yang, L., Chang, N., Zhao, X., Zhou, X., Dong, C., Liu, F., Yang, L., & Li, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01149 · Cited by 102
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Benetti, E., Mastrocola, R., Vitarelli, G., Cutrìn, J. C., Nigro, D., Chiazza, F., Mayoux, E., Collino, M., & Fantozzi, R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235069 · Cited by 102
FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation
Keinicke, H., Sun, G., Mentzel, C. M. J., Fredholm, M., John, L. M., Andersen, B., Raun, K., & Gerstenberg, M. K. (2020) · Endocrine Connections · doi:10.1530/ec-20-0152 · Cited by 104
Wree, A., Schlattjan, M., Bechmann, L. P., Claudel, T., Sowa, J., Stojaković, T., Scharnagl, H., Köfeler, H. C., Baba, H. A., Gerken, G., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2014.09.001 · Cited by 103
Self-citationThe NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
Self-citationXu, Y., Yang, C. N., Zhang, S., Li, J., Xiao, Q., & Huang, W. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00132 · Cited by 101
Inflammasome: A Double-Edged Sword in Liver Diseases
Luan, J., & Ju, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02201 · Cited by 96
Han, D., Kim, H., Kim, S., Le, Q. A., Han, S. Y., Bae, J., Shin, H. W., Kang, H., Han, K. H., Shin, J., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00737-9 · Cited by 101
The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders
Menini, S., Iacobini, C., Vitale, M., & Pugliese, G. (2020) · Cells · doi:10.3390/cells9081812 · Cited by 97
Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury
Frissen, M., Liao, L., Schneider, K. M., Djudjaj, S., Haybaeck, J., Wree, A., Rolle-Kampczyk, U. E., von Bergen�, M., Latz, E., Boor, P., et al. (2020) · Hepatology · doi:10.1002/hep.31494 · Cited by 93
Self-citationInterleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Knorr, J., Kaufmann, B. K., Inzaugarat, M. E., Holtmann, T. M., Geisler, L. J., Hundertmark, J., Kohlhepp, M. S., Boosheri, L. M., Chilin-Fuentes, D., Birmingham, A., et al. (2022) · Hepatology · doi:10.1002/hep.32776 · Cited by 99
Self-citationLipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
Iturbe-Rey, S., Maccali, C., Arrese, M. A., Aspichueta, P., de Oliveira, C. P. M. S., Castro, R. E., Lapitz, A., Izquierdo‐Sánchez, L., Bujanda, L., Perugorria, M. J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119053 · Cited by 102
Zhou, L., Wang, Y., Liu, Y., Mao, Y., Dong, W., Ding, Z.-N., Meng, G., Jiang, L., & Zhu, X. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002799 · Cited by 92
Schuster, S., Johnson, C. D., Hennebelle, M., Holtmann, T. M., Taha, A. Y., Kirpich, I., Eguchi, A., Ramsden, C. E., Papouchado, B. G., McClain, C. J., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m083741 · Cited by 91
Self-citationQiu, H., Liu, W., Lan, T., Pan, W., Chen, X., Wu, H., & Xu, D. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.238 · Cited by 90
Metadata
- Authors
- Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E.
- Affiliations
- University of California San Diego (US)
- Essen University Hospital (DE)
- Corresponding author
- Feldstein, Ariel E.
- ORCID
- Venue
- Journal of Molecular Medicine
- Published
- 2014-05-28
- Volume
- 92
- Issue
- 10
- Pages
- 1069-1082
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- PMC
- PMC4349416
- OpenAlex
- W1977508200
- Cited by
- 486
- References
- 43
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 31 · 2023: 64 · 2022: 66 · 2021: 63 · 2020: 69 · 2019: 27 · 2018: 37 · 2017: 33 · 2016: 27 · 2015: 17 · 2014: 3
- FWCI
- 20.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Americanae (AECID Library) (submittedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (U01AA022489)
- National Cancer Institute (P30CA023100)
- National Institute of Allergy and Infectious Diseases (AI52430, R01AI052430)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082451, R01DK076852, DK082451, DK-076852)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- NLRP3 inflammasome, non-alcoholic fatty liver disease, liver fibrosis, steatohepatitis, hepatic steatosis, NLRP3 knockout mice, pro-IL-1β, COL1A1, macrophage infiltration, liver inflammation, caspase-1
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Collagen Type I, alpha 1 Chain, Animals, Carrier Proteins, Female, Fibrosis, Humans, Liver, Male, Mice, Transgenic, RNA, Messenger, Collagen Type I, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
